As clinical trials for Alzheimer’s disease (AD) seek to enroll individuals at the earliest stages of the disease, it has become increasingly important to examine the impact of learning AD risk in cognitively normal individuals. Researchers can use amyloid brain imaging methods to identify participants who have Alzheimer’s brain pathology but no cognitive impairment and enroll them in AD clinical trials. This project generated data on how to appropriately enroll these individuals and safely disclose risk to them, while measuring performance bias on crucial outcome measures. The aims of the study are: 1) to determine whether disclosure of elevated brain amyloid will bias ADCS-Preclinical Alzheimer Cognitive Composite (ADCS-PACC) test results; 2) to determine whether disclosure of elevated brain amyloid will cause psychological distress; and 3) to explore how learning amyloid imaging disclosure will impact preventative health behaviors, advance planning for health (e.g. long-term care insurance decisions) and well-being (e.g. stigma, quality of life and relationships). A supplemental study explored how participants’ study partners understood and reacted to the biomarker result.
Collaboration: This multi-site project is led by co-PIs Dr. Jason Karlawish and Dr. Robert Green (Brigham & Women’s Hospital). Site PIs include Dr. Scott Roberts (University of Michigan) and Dr. Kathleen Welsh-Bohmer (Duke University).
Funding: National Institute on Aging: RF1-AG-047866
Publications:
Largent EA, Abera M, Harkins K, Feldman SJ, Uhlmann WR, Roberts JS, Karlawish J; REVEAL-SCAN Team. Family members’ perspectives on learning cognitively unimpaired older adults’ amyloid-β PET scan results. J Am Geriatr Soc. 2021 Nov;69(11):3203-3211. doi: 10.1111/jgs.17362. PMID: 34252201; PMCID: PMC8595546